Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies

Ronald Feld, Marianne Paesmans, Alison Gail Freifeld, Jean Klastersky, Philip A. Pizzo, Kenneth V I Rolston, Edward Rubenstein, James A. Talcott, Thomas J. Walsh

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Two multinational organizations, the Immunocompromised Host Society and the Multinational Association for Supportive Care in Cancer, have produced for investigators and regulatory bodies a set of guidelines on methodology for clinical trials involving patients with febrile neutropenia. The guidelines suggest that response (i.e., success of initial empirical antibiotic therapy without any modification) be determined at 72 h and again on day 5, and the reasons for modification should be stated. Blinding and stratification are to be encouraged, as should statistical consideration of trials specifically designed for showing equivalence. Patients enrolled in outpatient studies should be selected by use of a validated risk model, and patients should be carefully monitored after discharge from the hospital. Response and safety parameters should be recorded along with readmission rates. If studies use these guidelines, comparisons between studies will be simpler and will lead to further improvements in patient therapy.

Original languageEnglish (US)
Pages (from-to)1463-1468
Number of pages6
JournalClinical Infectious Diseases
Volume35
Issue number12
DOIs
StatePublished - Dec 15 2002

Fingerprint

Febrile Neutropenia
Immunocompromised Host
Outpatients
Clinical Trials
Guidelines
Neoplasms
Research Personnel
Anti-Bacterial Agents
Safety
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Methodology for clinical trials involving patients with cancer who have febrile neutropenia : Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. / Feld, Ronald; Paesmans, Marianne; Freifeld, Alison Gail; Klastersky, Jean; Pizzo, Philip A.; Rolston, Kenneth V I; Rubenstein, Edward; Talcott, James A.; Walsh, Thomas J.

In: Clinical Infectious Diseases, Vol. 35, No. 12, 15.12.2002, p. 1463-1468.

Research output: Contribution to journalArticle

Feld, Ronald ; Paesmans, Marianne ; Freifeld, Alison Gail ; Klastersky, Jean ; Pizzo, Philip A. ; Rolston, Kenneth V I ; Rubenstein, Edward ; Talcott, James A. ; Walsh, Thomas J. / Methodology for clinical trials involving patients with cancer who have febrile neutropenia : Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. In: Clinical Infectious Diseases. 2002 ; Vol. 35, No. 12. pp. 1463-1468.
@article{a1183a56228145979a5bbe9d612dfec5,
title = "Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies",
abstract = "Two multinational organizations, the Immunocompromised Host Society and the Multinational Association for Supportive Care in Cancer, have produced for investigators and regulatory bodies a set of guidelines on methodology for clinical trials involving patients with febrile neutropenia. The guidelines suggest that response (i.e., success of initial empirical antibiotic therapy without any modification) be determined at 72 h and again on day 5, and the reasons for modification should be stated. Blinding and stratification are to be encouraged, as should statistical consideration of trials specifically designed for showing equivalence. Patients enrolled in outpatient studies should be selected by use of a validated risk model, and patients should be carefully monitored after discharge from the hospital. Response and safety parameters should be recorded along with readmission rates. If studies use these guidelines, comparisons between studies will be simpler and will lead to further improvements in patient therapy.",
author = "Ronald Feld and Marianne Paesmans and Freifeld, {Alison Gail} and Jean Klastersky and Pizzo, {Philip A.} and Rolston, {Kenneth V I} and Edward Rubenstein and Talcott, {James A.} and Walsh, {Thomas J.}",
year = "2002",
month = "12",
day = "15",
doi = "10.1086/344650",
language = "English (US)",
volume = "35",
pages = "1463--1468",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Methodology for clinical trials involving patients with cancer who have febrile neutropenia

T2 - Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies

AU - Feld, Ronald

AU - Paesmans, Marianne

AU - Freifeld, Alison Gail

AU - Klastersky, Jean

AU - Pizzo, Philip A.

AU - Rolston, Kenneth V I

AU - Rubenstein, Edward

AU - Talcott, James A.

AU - Walsh, Thomas J.

PY - 2002/12/15

Y1 - 2002/12/15

N2 - Two multinational organizations, the Immunocompromised Host Society and the Multinational Association for Supportive Care in Cancer, have produced for investigators and regulatory bodies a set of guidelines on methodology for clinical trials involving patients with febrile neutropenia. The guidelines suggest that response (i.e., success of initial empirical antibiotic therapy without any modification) be determined at 72 h and again on day 5, and the reasons for modification should be stated. Blinding and stratification are to be encouraged, as should statistical consideration of trials specifically designed for showing equivalence. Patients enrolled in outpatient studies should be selected by use of a validated risk model, and patients should be carefully monitored after discharge from the hospital. Response and safety parameters should be recorded along with readmission rates. If studies use these guidelines, comparisons between studies will be simpler and will lead to further improvements in patient therapy.

AB - Two multinational organizations, the Immunocompromised Host Society and the Multinational Association for Supportive Care in Cancer, have produced for investigators and regulatory bodies a set of guidelines on methodology for clinical trials involving patients with febrile neutropenia. The guidelines suggest that response (i.e., success of initial empirical antibiotic therapy without any modification) be determined at 72 h and again on day 5, and the reasons for modification should be stated. Blinding and stratification are to be encouraged, as should statistical consideration of trials specifically designed for showing equivalence. Patients enrolled in outpatient studies should be selected by use of a validated risk model, and patients should be carefully monitored after discharge from the hospital. Response and safety parameters should be recorded along with readmission rates. If studies use these guidelines, comparisons between studies will be simpler and will lead to further improvements in patient therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037115343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037115343&partnerID=8YFLogxK

U2 - 10.1086/344650

DO - 10.1086/344650

M3 - Article

C2 - 12471564

AN - SCOPUS:0037115343

VL - 35

SP - 1463

EP - 1468

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -